ArriVent BioPharma, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ArriVent BioPharma, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($34.98M) | Nov 10, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($31.40M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($31.40M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($64.39M) | May 12, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($64.39M) | Aug 11, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($64.39M) | Nov 10, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($20.56M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($21.87M) | Aug 11, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($21.87M) | Nov 10, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($17.42M) | May 12, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($17.42M) | Aug 11, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($17.42M) | Nov 10, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($14.40M) | Nov 14, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($21.57M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($21.57M) | Aug 14, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($12.17M) | Nov 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($12.17M) | May 8, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($12.17M) | Aug 14, 2024 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($38.32M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($33.62M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($66.77M) | May 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($24.23M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($25.70M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($20.67M) | May 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($16.72M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($22.58M) | Aug 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($12.17M) | May 8, 2024 |